We acquire “mature” (i.e. post-patent expiry), established branded prescription medicines from large cap and specialty pharma.
We develop line extensions (new formulations or new markets) to the medicines we acquire. We also develop our own niche generic medicines in-house.
We currently own and market a portfolio of 17 medicines and operate in more than 130 markets globally.
Our dedicated team of regulatory, artwork, technical and project management experts has vast experience in transitioning medicines seamlessly into our manufacturing and distribution networks, and working with vendors to ensure there is no disruption in supply to wholesalers, hospitals, pharmacies and ultimately – and most importantly – patients.
Our chemists work with our regulatory, artwork and technical experts to make the most of the medicines we acquire, developing new formulations for new markets. They also work on developing and launching generic medicines for niche indications.
Once we have successfully transitioned an acquired medicine or launched a developed medicine, our In Line team takes over the life cycle management of the medicines, making sure we maintain the highest standard of ethical medical practice, manage our supply chain effectively and responsibly and deliver high-quality medicines to our patients.
We partner with distribution partners to offer as wide a market coverage as possible. Our network now covers over 130 markets. We have offices in Basildon, Copenhagen, Dubai, Sydney and Vadodara.
Our specialty pharma subsidiary, Pharmanovia, focuses upon in-licensing, out-licensing and development of both medicines and medical devices in the Nordics and Europe. Learn more at www.pharmanovia.com.
We are proud to be a member of EMIG, the Ethical Medicines Industry Group. Learn more at emig.org.uk.